Patents by Inventor Cristina LECCI

Cristina LECCI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Caffeine inhibitors of MTHFD2 and uses thereof
    Patent number: 12187728
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 19, 2022
    Date of Patent: January 7, 2025
    Assignee: Raze Therapeutics, Inc.
    Inventors: Nello Mainolfi, Mikel P. Moyer, Eddine Saiah, Cristina Lecci, Robert David Matthew Pace, Heather Tye, Julia Vile
  • Heteroaryl inhibitors of PAD4
    Patent number: 11897866
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: February 13, 2024
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Holly Atton, Edward Beaumont, Elise Gadouleau, Laura Gleave, Philip Stephen Kerry, Cristina Lecci, Mirco Meniconi, Nat Monck, Jordan Palfrey, Kostas Papadopoulos, Heather Tye, Philip A. Woods
  • Novel compounds for treatment of diseases related to DUX4 expression
    Publication number: 20230271953
    Abstract: The present invention relates to compounds that act as DUX4 repressors, suitable for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Application
    Filed: November 27, 2020
    Publication date: August 31, 2023
    Applicant: Facio Intellectual Property B.V.
    Inventors: Pui Leng Loke, Joris Herman De Maeyer, Robert David Matthew Pace, Simon Fletcher Elwood, Gregory Foulkes, Andrew Anighoro, Ainoa Rueda-Zubiaurre, Jonathan Philip Richards, Adam James Davenport, Cristina Lecci, Anthony Paul Dickie, Gerd Schnorrenberg
  • CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF
    Publication number: 20230067237
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: January 19, 2022
    Publication date: March 2, 2023
    Inventors: Nello MAINOLFI, Mikel P. MOYER, Eddine SAIAH, Cristina LECCI, Robert David Matthew PACE, Heather TYE, Julia VILE
  • Novel Ferroportin Inhibitors
    Publication number: 20220363675
    Abstract: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Application
    Filed: June 7, 2021
    Publication date: November 17, 2022
    Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • Caffeine inhibitors of MTHFD2 and uses thereof
    Patent number: 11370792
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: June 28, 2022
    Assignee: Raze Therapeutics, Inc.
    Inventors: Nello Mainolfi, Mikel P. Moyer, Eddine Saiah, Cristina Lecci, Robert David Matthew Pace, Heather Tye, Julia Vile
  • HETEROARYL INHIBITORS OF PAD4
    Publication number: 20220081418
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: November 9, 2021
    Publication date: March 17, 2022
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Holly Atton, Edward Beaumont, Elise Gadouleau, Laura Gleave, Philip Stephen Kerry, Cristina Lecci, Mirco Meniconi, Nat Monck, Jordan Palfrey, Kostas Papadopoulos, Heather Tye, Philip A. Woods
  • Heteroaryl inhibitors of PAD4
    Patent number: 11198681
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: December 14, 2021
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Holly Atton, Edward Beaumont, Elise Gadouleau, Laura Gleave, Philip Stephen Kerry, Cristina Lecci, Mirco Meniconi, Nat Monck, Jordan Palfrey, Kostas Papadopoulos, Heather Tye, Philip A. Woods
  • HETEROARYL INHIBITORS OF PAD4
    Publication number: 20210299115
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: May 12, 2021
    Publication date: September 30, 2021
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
  • Ferroportin inhibitors
    Patent number: 11066399
    Abstract: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: July 20, 2021
    Assignee: Vifor (International) AG
    Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • HETEROARYL INHIBITORS OF PAD4
    Publication number: 20210188810
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: February 22, 2017
    Publication date: June 24, 2021
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Holly Atton, Edward Beaumont, Elise Gadouleau, Laura Gleave, Philip Stephen Kerry, Cristina Lecci, Mirco Meniconi, Nat Monck, Jordan Palfrey, Kostas Papadopoulos, Heather Tye
  • Heteroaryl inhibitors of PAD4
    Patent number: 11026937
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: June 8, 2021
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
  • Novel Ferroportin Inhibitors
    Publication number: 20210139472
    Abstract: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Application
    Filed: December 3, 2020
    Publication date: May 13, 2021
    Applicant: Vifor (International) AG
    Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepard, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • Ferroportin inhibitors
    Patent number: 11001579
    Abstract: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: May 11, 2021
    Assignee: Vifor (International) AG
    Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • Ferroportin inhibitors
    Patent number: 10738041
    Abstract: The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: August 11, 2020
    Assignee: Vifor (International) AG
    Inventors: Franz Dürrenberger, Wilm Buhr, Susanna Burckhardt, Michael Burgert, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • Covalent inhibitors of PAD4
    Patent number: 10703741
    Abstract: The present invention provides compounds of formula I useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: July 7, 2020
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Edward Jean Beaumont, Rajesh Devraj, Philip Stephen Kerry, Gnanasambandam Kumaravel, Pui Leng Loke, Mirco Meniconi, Jordan John Palfrey, Carl North, Cristina Lecci, Heather Tye
  • HETEROARYL INHIBITORS OF PAD4
    Publication number: 20190358216
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: September 11, 2017
    Publication date: November 28, 2019
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
  • Novel Ferroportin Inhibitors
    Publication number: 20190345151
    Abstract: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Application
    Filed: June 12, 2019
    Publication date: November 14, 2019
    Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • Ferroportin inhibitors
    Patent number: 10364239
    Abstract: The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: July 30, 2019
    Assignee: Vifor (International) AG
    Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF
    Publication number: 20180370972
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 14, 2016
    Publication date: December 27, 2018
    Inventors: Nello Mainolfi, Mikel P. Moyer, Eddine Saiah, Cristina Lecci, Robert David Matthew Pace, Heather Tye, Julia Vile